Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases

Current Opinion in Chemical Biology

Volumn 8, Issue 4, 2004, Pages 432-441

  Mazitschek, Ralph ^a   Giannis, Athanassios ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Ang 1 2; Angiopoietin 1 2; EGF(R); epidermal growth factor (receptor); FGF(R); fibroblast growth factor (receptor); heat shock protein 90; HIF; HSP 90; hypoxia inducible factor; IGF1(R); insulin like growth factor 1 (receptor); PDGFR

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; CANERTINIB; ERLOTINIB; GEFITINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SULINDAC; SUNITINIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

ANGIOGENESIS; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; HUMAN; HYPERTENSION; IC 50; INHIBITION KINETICS; NONHUMAN; QT PROLONGATION; REVIEW; SUDDEN DEATH; THROMBOCYTOPENIA;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR;

EID: 3342940018     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2004.06.009     Document Type: Review

References (78)

1. Kamen BA, Cole PD, Bertino JR: Chemotherapeutic agents. In Cancer Medicine, Vol. 5. Edited by Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E. BCDecker; 2000:612-705.
2. Bosslet K., Straub R., Blumrich M., Czech J., Gerken M., Sperker B., Kroemer H.K., Gesson J.P., Koch M., Monneret C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 58:1998;1195-1201
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1971;1182-1186
4. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2:2002;727-739
5. Kerbel R.S. A cancer therapy resistant to resistance. Nature. 390:1997;335-336
6. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407
7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:1995;27-31
8. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:2003;401-410
9. Tonini T., Rossi F., Claudio P.P. Molecular basis of angiogenesis and cancer. Oncogene. 22:2003;6549-6556
10. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., Menger M.D., Ullrich A., Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18:2004;338-340
11. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., Stratton M.R. A cencus of human cancer genes. Nat Rev Cancer. 4:2004;177-183
12. Adams J., Huang P., Patrick D. A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. Curr Opin Chem Biol. 6:2002;486-492
13. Fischer O.M., Streit S., Hart S., Ullrich A. Beyond Herceptin and Gleevec. Curr Opin Chem Biol. 7:2003;490-495
14. Grosios K., Traxler P. Tyrosine kinase targets in drug discovery. Drugs of the Future. 28:2003;679-697
15. Petrova T.V., Makinen T., Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res. 253:1999;117-130
16. Veikkola T., Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol. 9:1999;211-220
17. Cross M.J., Dixelius J., Matsumoto T., Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci. 28:2003;488-494
18. Luttun A., Autiero M., Tjwa M., Carmeliet P. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets? Biochim Biophys Acta. 1654:2004;79-94
19. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med. 9:2003;669-676
20. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 34:2003;383-394
21. Wood J.M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., Hofmann F., Mestan J., Mett H., O'Reilly T., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60:2000;2178-2189
22. Manley P.W., Bold G., Bruggen J., Fendrich G., Furet P., Mestan J., Schnell C., Stolz B., Meyer T., Meyhack B., et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta. 1697:2004;17-27
23. Hennequin L.F., Stokes E.S., Thomas A.P., Johnstone C., Ple P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., Curwen J.O. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem. 45:2002;1300-1312 This paper describes the structure-activity relationships of a subset of anilinoquinazoline-based VEGF inhibitors and investigates the selectivity towards other kinases.
24. Cavalli A., Poluzzi E., De Ponti F., Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J Med Chem. 45:2002;3844-3853
25. Sun L., Liang C., Shirazian S., Zhou Y., Miller T., Cui J., Fukuda J.Y., Chu J.Y., Nematalla A., Wang X., et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 46:2003;1116-1119
26. Morimoto A.M., Tan N., West K., McArthur G., Toner G.C., Manning W.C., Smolich B.D., Cherrington J.M. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene. 23:2004;1618-1626
27. Gingrich D.E., Reddy D.R., Iqbal M.A., Singh J., Aimone L.D., Angeles T.S., Albom M., Yang S., Ator M.A., Meyer S.L., et al. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3- hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J Med Chem. 46:2003;5375-5388 This paper demonstrates the anti-tumor activity of CEP-5214 and describes some structure-activity relationship and the selectivity profile of CEP-5214. The authors also prove the in vivo activity of the prodrug CEP-7055.
28. Beebe J.S., Jani J.P., Knauth E., Goodwin P., Higdon C., Rossi A.M., Emerson E., Finkelstein M., Floyd E., Harriman S., et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 63:2003;7301-7309
29. Manley P.W., Furet P., Bold G., Bruggen J., Mestan J., Meyer T., Schnell C.R., Wood J., Haberey M., Huth A., et al. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 45:2002;5687-5693
30. Wu Z., Fraley M.E., Bilodeau M.T., Kaufman M.L., Tasber E.S., Balitza A.E., Hartman G.D., Coll K.E., Rickert K., Shipman J., et al. Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR. Bioorg Med Chem Lett. 14:2004;909-912
31. Fraley M.E., Arrington K.L., Buser C.A., Ciecko P.A., Coll K.E., Fernandes C., Hartman G.D., Hoffman W.F., Lynch J.J., McFall R.C., et al. Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding. Bioorg Med Chem Lett. 14:2004;351-355
32. LeCouter J., Moritz D.R., Li B., Phillips G.L., Liang X.H., Gerber H.P., Hillan K.J., Ferrara N. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science. 299:2003;890-893 The authors demonstrate that VEGF plays a broader role in tissue homeostasis than previously anticipated.
33. Carmeliet P., Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol. 13:2002;39-53
34. Reinmuth N., Liu W., Jung Y.D., Ahmad S.A., Shaheen R.M., Fan F., Bucana C.D., McMahon G., Gallick G.E., Ellis L.M. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 15:2001;1239-1241
35. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 277:1997;48-50
36. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 111:2003;1287-1295 This article demonstrates the advantage of blocking angiogenesis by targeting several growth factors simultaneously.
37. Zhou B.-N., Johnson R.K., Mattern M.R., Fisher P.W., Kingston D.G.I. The first naturally occurring Tie2 kinase inhibitor. Org Lett. 3:2001;4047-4049
38. Stieber F., Mazitschek R., Soric N., Giannis A., Waldmann H. Traceless solid-phase synthesis of 2-aminothiazoles: receptor tyrosine kinase inhibitors with dual selectivity for Tie-2 and VEGFR-2. Angew Chem Int Ed Engl. 41:2002;4757-4761
39. Rosenbaum C., Baumhof P., Mazitschek R., Muller O., Giannis A., Waldmann H. Synthesis and biological evaluation of an indomethacin library reveals a new class of angiogenesis-related kinase inhibitors. Angew Chem Int Ed Engl. 43:2004;224-228
40. Kissau L., Stahl P., Mazitschek R., Giannis A., Waldmann H. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. J Med Chem. 46:2003;2917-2931
41. Stahl P., Kissau L., Mazitschek R., Giannis A., Waldmann H. Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors. Angew Chem Int Ed Engl. 41:2002;1174-1178 The principle of natural product guided development of biological active molecules is applied for library design with a high hit rate. A modeling study gives insight in structure-activity relationship.
42. Wells A. EGF receptor. Int J Biochem Cell Biol. 31:1999;637-643
43. Spencer K.S., Graus-Porta D., Leng J., Hynes N.E., Klemke R.L. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol. 148:2000;385-397
44. Pao W., Miller V.A., Kris M.G. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol. 14:2004;33-40
45. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist. 9:2004;58-67 This review gives a critical overview of the clinical activity of EGFR inhibitors in certain cancer types and the range of potential therapeutic targets that exists within the HER signaling system.
46. Tamura K., Fukuoka M. Molecular target-based cancer therapy: tyrosine kinase inhibitors. Int J Clin Oncol. 8:2003;207-211
47. Allen L.F., Eiseman I.A., Fry D.W., Lenehan P.F. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol. 30:2003;65-78
48. Erlichman C., Boerner S.A., Hallgren C.G., Spieker R., Wang X.Y., James C.D., Scheffer G.L., Maliepaard M., Ross D.D., Bible K.C., et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10- hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 61:2001;739-748
49. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., Nunes M., Frost P., Discafani C.M. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 6:2000;1024-1028
50. Baserga R., Peruzzi F., Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 107:2003;873-877
51. Reinmuth N., Fan F., Liu W., Parikh A.A., Stoeltzing O., Jung Y.D., Bucana C.D., Radinsky R., Gallick G.E., Ellis L.M. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest. 82:2002;1377-1389
52. Bohula E.A., Playford M.P., Macaulay V.M. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs. 14:2003;669-682 The authors show the importance of IGF1R in various solid and hematological cancer types, providing the framework for future clinical trials. Furthermore, they report a selective small-molecule inhibitor of IGF1R.
53. Frank R.N. Diabetic retinopathy. N Engl J Med. 350:2004;48-58
54. De Meyts P., Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 1:2002;769-783
55. Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64:2004;236-242
56. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Akiyama M., Hideshima T., Chauhan D., Joseph M., Libermann T.A., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 5:2004;221-230
57. Sweeney C.J., Miller K.D., Sledge G.W. Jr. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med. 9:2003;24-29 This article reviews the reasons why angiogenic therapy has not kept its promises (yet).
58. Rafii S., Meeus S., Dias S., Hattori K., Heissig B., Shmelkov S., Rafii D., Lyden D. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol. 13:2002;61-67
59. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:1997;964-967
60. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 284:1999;1994-1998
61. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878
62. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 295:2002;1526-1528 This paper discusses the impact of p53 mutations on sensitivity of tumors to hypoxia and the implications for antiangiogenic therapy.
63. Blagosklonny M.V. Antiangiogenic therapy and tumor progression. Cancer Cell. 5:2004;13-17
64. Kieran M.W., Folkman J., Heymach J. Angiogenesis inhibitors and hypoxia. Nat Med. 9:2003;1104. (author reply 1104-1105.)
65. Höckel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 93:2001;266-276
66. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 7:2001;987-989
67. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., Park J.W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst. 95:2003;516-525
68. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62:2002;2478-2482
69. Sreedhar A.S., Söti C., Csermely P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta. 1697:2004;233-242
70. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 206:2004;149-157
71. Goldberg A.L., Rock K. Not just research tools-proteasome inhibitors offer therapeutic promise. Nat Med. 8:2002;338-340
72. Nawrocki S.T., Bruns C.J., Harbison M.T., Bold R.J., Gotsch B.S., Abbruzzese J.L., Elliott P., Adams J., McConkey D.J. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 1:2002;1243-1253
73. McCormick F. Cancer: survival pathways meet their end. Nature. 428:2004;267-269
74. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428:2004;332-337
75. Sawyers C.L. Will mTOR inhibitors make it as cancer drugs? Cancer Cell. 4:2003;343-348
76. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 8:2002;128-135
77. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N Engl J Med. 350:2004;2129-2139
78. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science. 304:2004;1497-1500